Literature DB >> 22938833

A multinational, multidisciplinary consensus for the diagnosis and management of spinal cord compression among patients with mucopolysaccharidosis VI.

Guirish A Solanki1, Tord D Alden, Barbara K Burton, Roberto Giugliani, Dafne D G Horovitz, Simon A Jones, Christina Lampe, Kenneth W Martin, Maura E Ryan, Matthias K Schaefer, Aisha Siddiqui, Klane K White, Paul Harmatz.   

Abstract

Cervical cord compression is a sequela of mucopolysaccharidosis VI, a rare lysosomal storage disorder, and has devastating consequences. An international panel of orthopedic surgeons, neurosurgeons, anesthesiologists, neuroradiologists, metabolic pediatricians, and geneticists pooled their clinical expertise to codify recommendations for diagnosing, monitoring, and managing cervical cord compression; for surgical intervention criteria; and for best airway management practices during imaging or anesthesia. The recommendations offer ideal best practices but also attempt to recognize the worldwide spectrum of resource availability. Functional assessments and clinical neurological examinations remain the cornerstone for identification of early signs of myelopathy, but magnetic resonance imaging is the gold standard for identification of cervical cord compression. Difficult airways of MPS VI patients complicate the anesthetic and, thus, the surgical management of cervical cord compression. All patients with MPS VI require expert airway management during any surgical procedure. Neurophysiological monitoring of the MPS VI patient during complex spine or head and neck surgery is considered standard practice but should also be considered for other procedures performed with the patient under general anesthesia, depending on the length and type of the procedure. Surgical interventions may include cervical decompression, stabilization, or both. Specific techniques vary widely among surgeons. The onset, presentation, and rate of progression of cervical cord compression vary among patients with MPS VI. The availability of medical resources, the expertise and experience of members of the treatment team, and the standard treatment practices vary among centers of expertise. Referral to specialized, experienced MPS treatment centers should be considered for high-risk patients and those requiring complex procedures. Therefore, the key to optimal patient care is to implement best practices through meaningful communication among treatment team members at each center and among MPS VI specialists worldwide.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22938833     DOI: 10.1016/j.ymgme.2012.07.018

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  11 in total

1.  Spinal cord issues in adult patients with MPS: transition of care survey.

Authors:  Kemel A Ghotme; Fernando Alvarado-Gomez; Christina Lampe; Klane K White; Martha Solano-Villareal; Roberto Giugliani; Paul R Harmatz
Journal:  Childs Nerv Syst       Date:  2018-05-27       Impact factor: 1.475

2.  Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI.

Authors:  Natalie E Taylor; Donald R Dengel; Troy C Lund; Kyle D Rudser; Paul J Orchard; Julia Steinberger; Chester B Whitley; Lynda E Polgreen
Journal:  J Pediatr Rehabil Med       Date:  2014

3.  Spinal cord compression in patients with mucopolysaccharidosis.

Authors:  Tobias Pantel; Mona Lindschau; Andreas M Luebke; Philip Kunkel; Marc Dreimann; Nicole Muschol; Sven O Eicker
Journal:  Eur Spine J       Date:  2022-03-10       Impact factor: 2.721

4.  Evaluation of spinal involvement in children with mucopolysaccharidosis VI: the role of MRI.

Authors:  Elif Bulut; Emine Pektas; Hatice S Sivri; Burcak Bilginer; Mumtaz M Umaroglu; Burce Ozgen
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

Review 5.  Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders.

Authors:  Linda Cassis; Elisenda Cortès-Saladelafont; Marta Molero-Luis; Delia Yubero; Maria Julieta González; Aida Ormazábal; Carme Fons; Cristina Jou; Cristina Sierra; Esperanza Castejon Ponce; Federico Ramos; Judith Armstrong; M Mar O'Callaghan; Mercedes Casado; Raquel Montero; Silvia Meavilla-Olivas; Rafael Artuch; Ivo Barić; Franco Bartoloni; Cinzia Maria Bellettato; Fedele Bonifazi; Adriana Ceci; Ljerka Cvitanović-Šojat; Christine I Dali; Francesca D'Avanzo; Ksenija Fumic; Viviana Giannuzzi; Christina Lampe; Maurizio Scarpa; Ángels Garcia-Cazorla
Journal:  Orphanet J Rare Dis       Date:  2015-12-30       Impact factor: 4.123

Review 6.  Assessing the impact of the five senses on quality of life in mucopolysaccharidoses.

Authors:  Roberto Giugliani; Paul Harmatz; Shuan-Pei Lin; Maurizio Scarpa
Journal:  Orphanet J Rare Dis       Date:  2020-04-19       Impact factor: 4.123

Review 7.  Surgical Management of Spinal Disorders in People with Mucopolysaccharidoses.

Authors:  Hidetomi Terai; Hiroaki Nakamura
Journal:  Int J Mol Sci       Date:  2020-02-10       Impact factor: 5.923

Review 8.  Diagnostic and treatment strategies in mucopolysaccharidosis VI.

Authors:  Filippo Vairo; Andressa Federhen; Guilherme Baldo; Mariluce Riegel; Maira Burin; Sandra Leistner-Segal; Roberto Giugliani
Journal:  Appl Clin Genet       Date:  2015-10-30

9.  Sensory-motor behavioral characterization of an animal model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI).

Authors:  Paola Saccone; Gabriella Cotugno; Fabio Russo; Rosa Mastrogiacomo; Alessandra Tessitore; Alberto Auricchio; Elvira De Leonibus
Journal:  Sci Rep       Date:  2014-01-10       Impact factor: 4.379

Review 10.  Orthopaedic challenges for mucopolysaccharidoses.

Authors:  Andrea Borgo; Andrea Cossio; Denise Gallone; Francesca Vittoria; Marco Carbone
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.